OMNIlife science™, Inc. Achieves Milestone with OMNIBotics® Active Spacer
1,000 Cases Completed with First Predictive Ligament Balancing Robot
RAYNHAM, Mass., Oct. 3, 2018 /PRNewswire/ — OMNIlife science, Inc. (“OMNI”), a privately-held medical technology company targeting the $15 billion global hip and knee replacement device market, reported today that the positive clinical benefits of the OMNIBotics® Robotic Active Spacer continue to be reinforced by more than 1,000 successful procedures performed to date. Orthopedic surgeons have been evaluating this revolutionary system that utilizes a miniature robot to ensure the ligaments will be “balanced” after the knee replacement.
Jeffrey H. DeClaire, M.D. of the Michigan Knee Institute in Rochester, Michigan, is one of the first orthopedic surgeons to use BalanceBot. In his opinion, “OMNIBotics, and the use of the BalanceBot device, is a significant improvement to the field of knee replacement. The ability to plan implant position to best balance the knee’s soft tissues using the Predictive Balance software, on top of the consistency and reproducibility that comes with robotics, is remarkable. The immediate results are noticeable, and I’m excited to continue monitoring my patients and track their recoveries.”